PEAKS AB: The fastest path to accurate antibody sequences

 

ON-DEMAND WEBINAR



What challenges do you face in characterizing monoclonal antibodies (mAbs) at the molecular level? 

Whether it's heterogeneity caused by truncation or glycation, or confounding isobaric amino acids, you've wished there was a better way.

Watch our webinar to learn about a novel, three-in-one solution for obtaining 100% accurate amino acid sequences for antibody proteins, powered by the PEAKS AB software. 

 

Copyright © 2017 Science Exchange, Inc. All Rights Reserved
Privacy Policy
 

Hear from proteomics analysis expert Wen Zhang, Ph.D., Senior Application Scientist at Bioinformatics Solutions, Inc.
The de novo antibody sequencing service offered by BSI is a 3-in-1 solution for obtaining 100% accurate amino acid sequences for your antibody proteins with unknown sequences.

BSI combines the state-of-the-art top-down and bottom-up MS technologies to achieve high accuracy of the constructed sequence with amino-acid level confidence. The latest EThcD fragmentation scheme is incorporated into the bottom-up MS workflow. The rich MS/MS spectra derived from EThcD fragmentation not only improves the accuracy and sensitivity of de novo sequencing, but also generates signature w-ion for direct discrimination of the isobaric amino acids, isoleucine and leucine.

In turn, from their bottom-up MS analysis, BSI derives the antibody protein sequences with isoleucine and leucine differentiation by EThcD method. In addition, the top-down MS workflow focuses on the intact mass of light and heavy chains. This addresses the antibody heterogeneity issues such as C-terminal lysine truncation and glycan forms, which cannot be well answered by bottom-up methods. Furthermore, the top-down MS result can further validate the bottom-up sequencing result. By integrating bottom-up MS analysis with EThcD and top-down MS approaches, the de novo antibody sequencing with Ile / Leu differentiation service offered by BSI can guarantee 100% sequence accuracy. 

You will learn about:

  • Intact mass analysis of antibody proteins; why is it important?
  • De novo antibody protein sequencing workflow used in PEAKS AB service: algorithm and experimental procedure
  • Isoleucine and leucine differentiation by using EThcD fragmentation methods

Who should attend:

  • Antibody drug discovery researchers
  • Scientists interested in antibody protein characterization
  • Researchers interested in de novo protein sequencing


About Our Speaker

Wen Zhang, Ph.D. Dr. Zhang is the Senior Application Scientist at Bioinformatics Solutions Inc. (BSI). Dr. Zhang received her Bachelor of Science in Biological Sciences at Peking University. She then moved to Canada where she was directly enrolled into a PhD program in Molecular Genetics at the University of Toronto. In her five-year PhD study, she focused primarily on studying human lung cancer proteomics by utilizing state-of-the-art liquid chromatography coupled tandem mass spectrometry technologies and a variety of molecular and cellular biology and biochemistry methods. With her rich experience in proteomics and MS data generation, processing and analysis, she joined BSI as an Application Scientist after graduation. Since then, she has advanced herself to leading the antibody protein de novo sequencing projects, which include intact mass, de novo sequencing, peptide mapping, post-translational modification, disulfide bond and N-linked glycan analyses.



 

Dr. Wen Zhang, Senior Application Scientist, Bioinformatics Solutions, Inc.